NXGL Quote, Financials, Valuation and Earnings

The Cooper Companies has a net margin of -23.57% compared to NexGel's net margin of 11.54%. NexGel's return on equity of -67.5% beat The Cooper Companies's return on equity of 5.02%.

NexGel has a consensus price target of --, signalling upside risk potential of 26.58%. On the other hand The Cooper Companies has an analysts' consensus of $112.01 which suggests that it could grow by 20.69%. Given that NexGel has higher upside potential than The Cooper Companies, analysts believe NexGel is more attractive than The Cooper Companies.

NexGel has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison The Cooper Companies has a beta of 0.968, suggesting its less volatile than the S&P 500 by 3.236%.

NexGel has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. The Cooper Companies offers a yield of 0% to investors and pays a quarterly dividend of $0.01 per share. NexGel pays -- of its earnings as a dividend. The Cooper Companies pays out -- of its earnings as a dividend.

NexGel quarterly revenues are $2.9M, which are smaller than The Cooper Companies quarterly revenues of $1B. NexGel's net income of -$693K is lower than The Cooper Companies's net income of $117.5M. Notably, NexGel's price-to-earnings ratio is -- while The Cooper Companies's PE ratio is 47.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NexGel is 4.32x versus 4.78x for The Cooper Companies. Usually stocks with elevated PS ratios are considered overvalued.

OrthoPediatrics has a net margin of -23.57% compared to NexGel's net margin of -14.51%. NexGel's return on equity of -67.5% beat OrthoPediatrics's return on equity of -7.63%.

NexGel has a consensus price target of --, signalling upside risk potential of 26.58%. On the other hand OrthoPediatrics has an analysts' consensus of $40.17 which suggests that it could grow by 77.93%. Given that OrthoPediatrics has higher upside potential than NexGel, analysts believe OrthoPediatrics is more attractive than NexGel.

NexGel has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison OrthoPediatrics has a beta of 1.143, suggesting its more volatile than the S&P 500 by 14.295%.

NexGel has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OrthoPediatrics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NexGel pays -- of its earnings as a dividend. OrthoPediatrics pays out -- of its earnings as a dividend.

NexGel quarterly revenues are $2.9M, which are smaller than OrthoPediatrics quarterly revenues of $54.6M. NexGel's net income of -$693K is higher than OrthoPediatrics's net income of -$7.9M. Notably, NexGel's price-to-earnings ratio is -- while OrthoPediatrics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NexGel is 4.32x versus 2.73x for OrthoPediatrics. Usually stocks with elevated PS ratios are considered overvalued.

Innovative Eyewear has a net margin of -23.57% compared to NexGel's net margin of -678.5%. NexGel's return on equity of -67.5% beat Innovative Eyewear's return on equity of -113.55%.

NexGel has a consensus price target of --, signalling upside risk potential of 26.58%. On the other hand Innovative Eyewear has an analysts' consensus of -- which suggests that it could grow by 144.76%. Given that Innovative Eyewear has higher upside potential than NexGel, analysts believe Innovative Eyewear is more attractive than NexGel.

NexGel has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Innovative Eyewear has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

NexGel has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Innovative Eyewear offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NexGel pays -- of its earnings as a dividend. Innovative Eyewear pays out -- of its earnings as a dividend.

NexGel quarterly revenues are $2.9M, which are larger than Innovative Eyewear quarterly revenues of $253.6K. NexGel's net income of -$693K is higher than Innovative Eyewear's net income of -$1.7M. Notably, NexGel's price-to-earnings ratio is -- while Innovative Eyewear's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NexGel is 4.32x versus 3.73x for Innovative Eyewear. Usually stocks with elevated PS ratios are considered overvalued.

Staar Surgical has a net margin of -23.57% compared to NexGel's net margin of 11.27%. NexGel's return on equity of -67.5% beat Staar Surgical's return on equity of 5.46%.

NexGel has a consensus price target of --, signalling upside risk potential of 26.58%. On the other hand Staar Surgical has an analysts' consensus of $41.89 which suggests that it could grow by 67.74%. Given that Staar Surgical has higher upside potential than NexGel, analysts believe Staar Surgical is more attractive than NexGel.

NexGel has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Staar Surgical has a beta of 0.587, suggesting its less volatile than the S&P 500 by 41.304%.

NexGel has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Staar Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NexGel pays -- of its earnings as a dividend. Staar Surgical pays out -- of its earnings as a dividend.

NexGel quarterly revenues are $2.9M, which are smaller than Staar Surgical quarterly revenues of $88.6M. NexGel's net income of -$693K is lower than Staar Surgical's net income of $10M. Notably, NexGel's price-to-earnings ratio is -- while Staar Surgical's PE ratio is 56.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NexGel is 4.32x versus 3.62x for Staar Surgical. Usually stocks with elevated PS ratios are considered overvalued.